Alpha Tau at JPM

 Alpha Tau Medical is a biotech company working on new modes of focal alpha-radiation treatment for various cancers. The company’s delivery Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to release high-energy dosages over a range of just a few millimeters – giving a high level of precision that will target the tumor only while sparing nearby healthy tissues. Alpha DaRT is administered by inserting tiny amounts of radiu-224 directly into the tumor cells, where it will decay rapidly, releasing alpha particles directly into the cancer cells. These particles themselves have a short half-life, preventing their spread outside of the target area.

In recent updates, Alpha Tau has outlined several steps that have put the company on the track toward active clinical trials. In the UK, the company has received regulatory approval for a trial in the treatment of squamous cell carcinoma of the vulva, while in Canada, regulatory authorities have approved a second site for a clinical trial in the treatment of advanced pancreatic cancer.

The company has several anticipated milestones coming in the near-term, including an Israeli feasibility trial for the treatment of pancreatic tumors to start in 1Q23, and Canadian approval to start a feasibility trial in the treatment of liver cancer, also in 1Q23.

Ladenburg Thalmann analyst Jeffrey Cohen covers this early-stage biotech, and takes an upbeat stance, based on the quality of the program and the plethora of upcoming catalysts.

“DRTS has demonstrated competency and clinical execution, in our opinion. We also note the continued efforts around building a strong body of data to support the clinical and regulatory opportunities for the Alpha DaRT technology. Overall, we are encouraged by the progress to date and the multiple near-term milestones as well as potential catalysts. As such, we continue to view DRTS as an attractive investment opportunity compared to peers,” Cohen wrote.

In line with his optimistic approach, Cohen gives DRTS shares a Buy rating, and his $18 price target suggests an impressive 460% potential upside for the coming year. (To watch Cohen’s track record, click here)

Cohen is not the only analyst to see a solid upside here; all three of this stock’s recent reviews are positive, for a Strong Buy consensus rating. The stock is trading for $3.21, implies a gain of ~450% on the one-year horizon.

https://www.tipranks.com/news/article/2-strong-buy-penny-stocks-with-over-400-upside-on-the-horizon